Regeneron Pharmaceuticals, Inc. Stock

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (53.7%); - revenues from collaboration agreements (42.7%): collaboration with Sanofi (74.8% of revenues), Bayer (24.7%) and other (0.5%); - revenues from sales of technology licenses and subcontracted research services (3.6%). At the end of 2024, the group had a portfolio of approximately 40 products in clinical development.